[
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "header",
    "content": "2 INTRODUCTION",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading1",
      "entity": [],
      "roi_id": {
        "para": "3904ac35-39db-4957-be52-90201cc38748",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "a0a903f2-32fd-48aa-b559-591eaac1dd49",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "adf62e39-87c4-46b4-b421-c07e709cbe60",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 1,
    "qc_change_type": "modify",
    "line_id": "3904ac35-39db-4957-be52-90201cc38748",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Capivasertib (AZD5363), a novel pyrrolopyrimidine-derived compound, is a potent, selective inhibitor of the kinase activity of all 3 isoforms of AKT (Davies et al 2012).",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f66fe0aa-0290-4253-9357-e42e10af970f",
        "childbox": "52dc5287-45b4-4599-b7f1-7213b8b1660e",
        "subtext": "3fdefd9b-8324-4731-9bc3-36e56e081a29"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "1d51e9ad-4c81-498f-a73a-56be911e5c49",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "3fdefd9b-8324-4731-9bc3-36e56e081a29",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 2,
    "qc_change_type": "modify",
    "line_id": "f66fe0aa-0290-4253-9357-e42e10af970f52dc5287-45b4-4599-b7f1-7213b8b1660e3fdefd9b-8324-4731-9bc3-36e56e081a29",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "AstraZeneca is developing capivasertib for use in combination with other anticancer agents for a range of therapeutic indications, including prostate cancer and breast cancer.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f66fe0aa-0290-4253-9357-e42e10af970f",
        "childbox": "41472390-6fb6-4655-aa2c-99dd1a0fd2a2",
        "subtext": "0e239c34-d5be-47e2-b5f2-417fbbf81e79"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "49468688-06bc-4132-b496-e1b1b3f8d4ce",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "0e239c34-d5be-47e2-b5f2-417fbbf81e79",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 3,
    "qc_change_type": "modify",
    "line_id": "f66fe0aa-0290-4253-9357-e42e10af970f41472390-6fb6-4655-aa2c-99dd1a0fd2a20e239c34-d5be-47e2-b5f2-417fbbf81e79",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "The AKT serine/threonine protein kinases (AKT1, AKT2, AKT3) are key downstream effectors of the PI3K/AKT/mTOR pathway, mediating cell proliferation and resistance to apoptosis, and are activated in a wide range of malignancies (Lindsley 2010).",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3c5b12b8-85ee-4cca-832e-2631b7ef92aa",
        "childbox": "1c3e998a-ebd7-4686-be82-c03e987f1dd6",
        "subtext": "3decb25b-1716-45f6-9afe-08510562abc4"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "be7d68b5-e656-4c81-87eb-2d95d74fb028",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "3decb25b-1716-45f6-9afe-08510562abc4",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 4,
    "qc_change_type": "modify",
    "line_id": "3c5b12b8-85ee-4cca-832e-2631b7ef92aa1c3e998a-ebd7-4686-be82-c03e987f1dd63decb25b-1716-45f6-9afe-08510562abc4",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "AKT activation in tumours is largely due to input from other signalling pathways upstream of AKT, including loss of PTEN function and mutations in the catalytic subunit of PI3K (PIK3CA) (Yi and Lauring 2015).",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3c5b12b8-85ee-4cca-832e-2631b7ef92aa",
        "childbox": "c6ea4196-13bb-49c2-aead-c7b268fae5b5",
        "subtext": "77e9dadf-edc1-4c35-99e3-1bd4d8f97eb0"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "026ff20f-0af8-40cd-a254-37013d3b9bbc",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "77e9dadf-edc1-4c35-99e3-1bd4d8f97eb0",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 5,
    "qc_change_type": "modify",
    "line_id": "3c5b12b8-85ee-4cca-832e-2631b7ef92aac6ea4196-13bb-49c2-aead-c7b268fae5b577e9dadf-edc1-4c35-99e3-1bd4d8f97eb0",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  },
  {
    "section_level": "",
    "CPT_section": "Unmapped",
    "type": "text",
    "content": "Investigators should be familiar with the current capivasertib Investigator’s Brochure (IB).",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e1aec867-bd34-4013-a6d7-e72d3ee1a3a8",
        "childbox": "c7462ac8-f157-415d-922e-11de8c7a66a4",
        "subtext": "688db965-01df-42fa-a7ff-0c0bc01b9bab"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "doc_id": "fa386108-6df3-4188-b897-4f078d2b23f0",
      "DStrike": false,
      "Emboss": false,
      "group_type": "fontInfo",
      "hierarchy": "paragraph",
      "Highlight": "",
      "id": "e90c1318-2a2b-4e10-8af0-fa40a98b0c6e",
      "Imprint": false,
      "iqv_standard_term": "",
      "Italics": false,
      "link_id": "e066c0c8-8cf9-11ed-b3d7-005056ab6469",
      "link_id_level2": "",
      "link_id_level3": "",
      "link_id_level4": "",
      "link_id_level5": "",
      "link_id_level6": "",
      "link_id_subsection1": "",
      "link_id_subsection2": "",
      "link_id_subsection3": "",
      "Outline": false,
      "parent_id": "688db965-01df-42fa-a7ff-0c0bc01b9bab",
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "level_1_CPT_section": "Unmapped",
    "file_section": "INTRODUCTION",
    "file_section_num": "2",
    "file_section_level": "1",
    "seq_num": 6,
    "qc_change_type": "modify",
    "line_id": "e1aec867-bd34-4013-a6d7-e72d3ee1a3a8c7462ac8-f157-415d-922e-11de8c7a66a4688db965-01df-42fa-a7ff-0c0bc01b9bab",
    "aidocid": "fa386108-6df3-4188-b897-4f078d2b23f0",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "section_locked": false
  }
]
